How Precise are Nanomedicines in Overcoming the Blood–Brain Barrier? A Comprehensive Review of the Literature

References

• Nguyen TT, Dung Nguyen TT, Vo TK, et al. Nanotechnology-based drug delivery for central nervous system disorders. Biomed Pharmacother. 2021;143:112117. doi:10.1016/j.biopha.2021.112117
   PubMed Web of Science ®Google Scholar
• Mehndiratta MM, Aggarwal V. Neurological disorders in India: past, present, and next steps. Lancet Glob Health. 2021;9(8):e1043–e1044. doi:10.1016/S2214-109X(21)00214-X
   PubMed Web of Science ®Google Scholar
• Upadhya M, Jimmy N, Jaison JM, et al. Drug utilization evaluation of medications used in the management of neurological disorders. Global Health J. 2023. doi:10.1016/j.glohj.2023.07.006
   Google Scholar
• Van Giau V, An SSA, Bagyinszky E, Kim S. Gene panels and primers for next generation sequencing studies on neurodegenerative disorders. Mol Cell Toxicol. 2015;11(2):89–143. doi:10.1007/s13273-015-0011-9
   Web of Science ®Google Scholar
• Re F, Gregori M, Masserini M. Nanotechnology for neurodegenerative disorders. Maturitas. 2012;73(1):45–51. doi:10.1016/j.maturitas.2011.12.015
   PubMed Web of Science ®Google Scholar
• Bioscience biotechnology research communications. Emerging applications of nanotechnology in neurological disorders: recent review. Available from: https://bbrc.in/emerging-applications-of-nanotechnology-in-neurological-disorders-recent-meta-review/. Accessed August 4, 2023.
   Google Scholar
• Chhabra R, Tosi G, Grabrucker AM. Emerging use of nanotechnology in the treatment of neurological disorders. Curr Pharm Des. 2015;21(22):3111–3130. doi:10.2174/1381612821666150531164124
   PubMed Web of Science ®Google Scholar
• Parveen S, Misra R, Sahoo SK. Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging. Nanomed Nanotechnol Biol Med. 2012;8(2):147–166. doi:10.1016/j.nano.2011.05.016
   PubMed Web of Science ®Google Scholar
• Kabanov AV, Batrakova EV. New technologies for drug delivery across the blood brain barrier. Curr Pharm Des. 2004;10(12):1355–1363.
   PubMed Web of Science ®Google Scholar
• Luo M, Lee LKC, Peng B, Choi CHJ, Tong WY, Voelcker NH. Delivering the promise of gene therapy with nanomedicines in treating central nervous system diseases. Adv Sci 2022;9(26):2201740. doi:10.1002/advs.202201740
   Web of Science ®Google Scholar
• Mohapatra P, Chandrasekaran N. Wnt/β-catenin targeting in liver carcinoma through nanotechnology-based drug repurposing: a review. Biomed Pharmacother. 2022;155:113713. doi:10.1016/j.biopha.2022.113713
   PubMed Web of Science ®Google Scholar
• Nehra M, Uthappa UT, Kumar V, et al. Nanobiotechnology-assisted therapies to manage brain cancer in personalized manner. J Control Release. 2021;338:224–243. doi:10.1016/j.jconrel.2021.08.027
   PubMed Web of Science ®Google Scholar
• Liu Z, Jiang W, Nam J, Moon JJ, Kim BYS. Immunomodulating nanomedicine for cancer therapy. Nano Lett. 2018;18(11):6655–6659. doi:10.1021/acs.nanolett.8b02340
   PubMed Web of Science ®Google Scholar
• Safary A, Akbarzadeh Khiavi M, Mousavi R, Barar J, Rafi MA. Enzyme replacement therapies: what is the best option? Bioimpacts. 2018;8(3):153–157. doi:10.15171/bi.2018.17
   PubMed Web of Science ®Google Scholar
• Muro S. New biotechnological and nanomedicine strategies for treatment of lysosomal storage disorders. WIREs Nanomed Nanobiotechnol. 2010;2(2):189–204. doi:10.1002/wnan.73
   Google Scholar
• Grosso AD, Galliani M, Angella L, et al. Brain-targeted enzyme-loaded nanoparticles: a breach through the blood-brain barrier for enzyme replacement therapy in Krabbe disease. Sci Adv. 2019. doi:10.1126/sciadv.aax7462
   Web of Science ®Google Scholar
• Sun C, Ding Y, Zhou L, et al. Noninvasive nanoparticle strategies for brain tumor targeting. Nanomed Nanotechnol Biol Med. 2017;13(8):2605–2621. doi:10.1016/j.nano.2017.07.009
   PubMed Web of Science ®Google Scholar
• Olivier JC. Drug transport to brain with targeted nanoparticles. NeuroRx. 2005;2(1):108–119. doi:10.1602/neurorx.2.1.108
   PubMedGoogle Scholar
• Rizvi SAA, Saleh AM. Applications of nanoparticle systems in drug delivery technology. Saudi Pharm J. 2018;26(1):64–70. doi:10.1016/j.jsps.2017.10.012
   PubMed Web of Science ®Google Scholar
• Iqubal A, Iqubal MK, Khan A, Ali J, Baboota S, Haque SE. Gene therapy, A novel therapeutic tool for neurological disorders: current progress, challenges and future prospective. Curr Gene Ther. 2020;20(3):184–194. doi:10.2174/1566523220999200716111502
   PubMed Web of Science ®Google Scholar
• Sundarrajan S, Venkatesan A, Kumar SU, et al. Exome sequence analysis of rare frequency variants in Late-Onset Alzheimer Disease. Metab Brain Dis. 2023;38(6):2025–2036. doi:10.1007/s11011-023-01221-7
   PubMed Web of Science ®Google Scholar
• Cao Y, Zhang R. The application of nanotechnology in treatment of Alzheimer’s disease. Frontiers in Bioengineering and Biotechnology; 2022. Available from: https://www.frontiersin.org/articles/10.3389/fbioe.2022.1042986. Accessed August 13, 2023.
   Google Scholar
• Sood S, Jain K, Gowthamarajan K. Intranasal therapeutic strategies for management of Alzheimer’s disease. J Drug Target. 2014;22(4):279–294. doi:10.3109/1061186X.2013.876644
   PubMed Web of Science ®Google Scholar
• Sabbagh MN. Alzheimer’s Disease drug development pipeline 2020. J Prev Alzheimers Dis. 2020;7(2):66–67. doi:10.14283/jpad.2020.12
   PubMed Web of Science ®Google Scholar
• Wilczewska AZ, Niemirowicz K, Markiewicz KH, Car H. Nanoparticles as drug delivery systems. Pharmacol Rep. 2012;64(5):1020–1037. doi:10.1016/S1734-1140(12)70901-5
   PubMed Web of Science ®Google Scholar
• Lamptey RNL, Chaulagain B, Trivedi R, Gothwal A, Layek B, Singh J. A review of the common neurodegenerative disorders: current therapeutic approaches and the potential role of nanotherapeutics. Int J Mol Sci. 2022;23(3):1851. doi:10.3390/ijms23031851
   PubMed Web of Science ®Google Scholar
• Spires-Jones TL, Attems J, Thal DR. Interactions of pathological proteins in neurodegenerative diseases. Acta Neuropathol. 2017;134(2):187–205. doi:10.1007/s00401-017-1709-7
   PubMed Web of Science ®Google Scholar
• Schulz-Schaeffer W. The synaptic pathology of α-synuclein aggregation in dementia with Lewy bodies, Parkinson’s disease and Parkinson’s disease dementia. Acta Neuropathol. 2010;120:131–143. doi:10.1007/s00401-010-0711-0
   PubMed Web of Science ®Google Scholar
• Mavridis IN, Meliou M, Pyrgelis ES, Agapiou E. Chapter 1 - Nanotechnology and Parkinson’s disease. In: Grumezescu AM, editor. Design of Nanostructures for Versatile Therapeutic Applications. William Andrew Publishing. 2018:1–29. doi:10.1016/B978-0-12-813667-6.00001-2
   Google Scholar
• Ganesan P, Ko HM, Kim IS, Choi DK. Recent trends in the development of nanophytobioactive compounds and delivery systems for their possible role in reducing oxidative stress in Parkinson’s disease models. Int J Nanomed. 2015;10:6757–6772. doi:10.2147/IJN.S93918
   PubMed Web of Science ®Google Scholar
• Dong X, Gao J, Su Y, Wang Z. Nanomedicine for Ischemic Stroke. Int J Mol Sci. 2020;21(20):7600. doi:10.3390/ijms21207600
   PubMed Web of Science ®Google Scholar
• Fornage M Grand challenges in stroke genomics. Frontiers in Stroke; 2022. Available from: https://www.frontiersin.org/articles/10.3389/fstro.2022.984176. Accessed August 13, 2023.
   Google Scholar
• Tsivgoulis G, Katsanos AH, Alexandrov AV. Reperfusion therapies of acute ischemic stroke: potentials and failures. Front Neurol. 2014;5:215. doi:10.3389/fneur.2014.00215
   PubMed Web of Science ®Google Scholar
• Ostrom QT, Cioffi G, Gittleman H, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012–2016. Neuro-Oncology. 2019;21(Supplement_5):v1–v100. doi:10.1093/neuonc/noz150
   PubMedGoogle Scholar
• Khaddour K, Johanns TM, Ansstas G. The Landscape of Novel therapeutics and challenges in glioblastoma multiforme: contemporary state and future directions. Pharmaceuticals. 2020;13(11):389. doi:10.3390/ph13110389
   Web of Science ®Google Scholar
• Ijaz I, Gilani E, Nazir A, Bukhari A. Detail review on chemical, physical and green synthesis, classification, characterizations and applications of nanoparticles. Green Chem Lett Rev. 2020;13(3):223–245. doi:10.1080/17518253.2020.1802517
   Web of Science ®Google Scholar
• Kelley SO, Mirkin CA, Walt DR, Ismagilov RF, Toner M, Sargent EH. Advancing the speed, sensitivity and accuracy of biomolecular detection using multi-length-scale engineering. Nature Nanotech. 2014;9(12):969–980. doi:10.1038/nnano.2014.261
   PubMed Web of Science ®Google Scholar
• Zhang TT, Li W, Meng G, Wang P, Liao W. Strategies for transporting nanoparticles across the blood–brain barrier. Biomater Sci 2016;4(2):219–229. doi:10.1039/C5BM00383K
   PubMed Web of Science ®Google Scholar
• Prabhakar P, Ahmed ABA, Chidambaram SB. the role of phloridzin and its possible potential therapeutic effect on Parkinson’s disease. Int J Nutr Pharmacol Neurol Dis. 2020;10(2):69. doi:10.4103/ijnpnd.ijnpnd_80_19
   Google Scholar
• Varallyay CG, Nesbit E, Fu R, et al. High-resolution steady-state cerebral blood volume maps in patients with central nervous system neoplasms using ferumoxytol, a superparamagnetic iron oxide nanoparticle. J Cereb Blood Flow Metab. 2013;33(5):780–786. doi:10.1038/jcbfm.2013.36
   PubMed Web of Science ®Google Scholar
• Gambaryan PY, Kondrasheva IG, Severin ES, Guseva AA, Kamensky AA. Increasing the efficiency of parkinson’s disease treatment using a poly(lactic-co-glycolic acid) (PLGA) Based L-DOPA delivery system. Exp Neurobiol. 2014;23(3):246–252. doi:10.5607/en.2014.23.3.246
   PubMedGoogle Scholar
• Feng Y, Panwar N, Tng DJH, Tjin SC, Wang K, Yong KT. The application of mesoporous silica nanoparticle family in cancer theranostics. Coord Chem Rev. 2016;319:86–109. doi:10.1016/j.ccr.2016.04.019
   Web of Science ®Google Scholar
• Lux F, Tran VL, Thomas E, et al. AGuIX® from bench to bedside—Transfer of an ultrasmall theranostic gadolinium-based nanoparticle to clinical medicine. BJR. 2019;92(1093):20180365. doi:10.1259/bjr.20180365
   Google Scholar
• Gilert A, Machluf M. Nano to micro delivery systems: targeting angiogenesis in brain tumors. Vasc Cell. 2010;2(1):20. doi:10.1186/2040-2384-2-20
   Google Scholar
• Lochhead JJ, Thorne RG. Intranasal delivery of biologics to the central nervous system. Adv Drug Delivery Rev. 2012;64(7):614–628. doi:10.1016/j.addr.2011.11.002
   PubMed Web of Science ®Google Scholar
• Cui Z, Lockman PR, Atwood CS, et al. Novel d-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer’s and other CNS diseases. Eur J Pharm Biopharm. 2005;59(2):263–272. doi:10.1016/j.ejpb.2004.07.009
   PubMed Web of Science ®Google Scholar
• Wilson B, Samanta MK, Santhi K, Kumar KPS, Paramakrishnan N, Suresh B. Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer’s disease. Brain Res. 2008;1200:159–168. doi:10.1016/j.brainres.2008.01.039
   PubMed Web of Science ®Google Scholar
• Jayant RD, Sosa D, Kaushik A, et al. Current status of non-viral gene therapy for CNS disorders. Expert Opin Drug Delivery. 2016;13(10):1433–1445. doi:10.1080/17425247.2016.1188802
   PubMed Web of Science ®Google Scholar
• Wei QY, Xu YM, Lau ATY. Recent progress of nanocarrier-based therapy for solid malignancies. Cancers. 2020;12(10):2783. doi:10.3390/cancers12102783
   PubMed Web of Science ®Google Scholar
• Suk JS, Xu Q, Kim N, Hanes J, Ensign LM. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv. Drug Delivery Rev. 2016;99:28–51. doi:10.1016/j.addr.2015.09.012
   PubMed Web of Science ®Google Scholar
• Chopade P, Chopade N, Zhao Z, Mitragotri S, Liao R, Chandran Suja V. Alzheimer’s and Parkinson’s disease therapies in the clinic. Bioeng Transl Med. 2023;8(1):e10367. doi:10.1002/btm2.10367
   PubMed Web of Science ®Google Scholar
• Mirón-Barroso S, Domènech EB, Trigueros S. Nanotechnology-based strategies to overcome current barriers in gene delivery. Int J Mol Sci. 2021;22(16):8537. doi:10.3390/ijms22168537
   PubMed Web of Science ®Google Scholar
• Farooque F, Wasi M, Mughees MM. Liposomes as drug delivery system: an updated review. J Drug Delivery Ther. 2021;11(5–S):149–158. doi:10.22270/jddt.v11i5-S.5063
   Google Scholar
• Lopez-Barbosa N, Garcia JG, Cifuentes J, et al. Multifunctional magnetite nanoparticles to enable delivery of siRNA for the potential treatment of Alzheimer’s. Drug Deliv. 2020;27(1):864–875. doi:10.1080/10717544.2020.1775724
   PubMed Web of Science ®Google Scholar
• Arora S, Layek B, Singh J. Design and validation of liposomal ApoE2 gene delivery system to evade blood-brain barrier for effective treatment of Alzheimer’s disease. Mol Pharmaceut. 2020. doi:10.1021/acs.molpharmaceut.0c00461
   Web of Science ®Google Scholar
• Sahoo NG, Rana S, Cho JW, Li L, Chan SH. Polymer nanocomposites based on functionalized carbon nanotubes. Prog Polym Sci. 2010;35(7):837–867. doi:10.1016/j.progpolymsci.2010.03.002
   Web of Science ®Google Scholar
• Kurawattimath V, Wilson B, Geetha KM. Nanoparticle-based drug delivery across the blood-brain barrier for treating malignant brain glioma. OpenNano. 2023;10:100128. doi:10.1016/j.onano.2023.100128
   Google Scholar
• Vogelbaum MA, Aghi MK. Convection-enhanced delivery for the treatment of glioblastoma. Neuro-Oncology. 2015;17(suppl_2):ii3–ii8. doi:10.1093/neuonc/nou354
   PubMedGoogle Scholar
• Pawar S, Koneru T, McCord E, Tatiparti K, Sau S, Iyer AK. LDL receptors and their role in targeted therapy for glioma: a review. Drug Discovery Today. 2021;26(5):1212–1225. doi:10.1016/j.drudis.2021.02.008
   PubMed Web of Science ®Google Scholar
• Begines B, Ortiz T, Pérez-Aranda M, et al. Polymeric nanoparticles for drug delivery: recent developments and future prospects. Nanomaterials. 2020;10(7):1403. doi:10.3390/nano10071403
   Web of Science ®Google Scholar
• Locatelli E, Comes Franchini M. Biodegradable PLGA-b-PEG polymeric nanoparticles: synthesis, properties, and nanomedical applications as drug delivery system. J Nanopart Res. 2012;14(12):1316. doi:10.1007/s11051-012-1316-4
   Web of Science ®Google Scholar
• Fan S, Zheng Y, Liu X, et al. Curcumin-loaded PLGA-PEG nanoparticles conjugated with B6 peptide for potential use in Alzheimer’s disease. Drug Delivery. 2018;25(1):1091–1102. doi:10.1080/10717544.2018.1461955
   PubMed Web of Science ®Google Scholar
• Carradori D, Balducci C, Re F, et al. Antibody-functionalized polymer nanoparticle leading to memory recovery in Alzheimer’s disease-like transgenic mouse model. Nanomed Nanotechnol Biol Med. 2018;14(2):609–618. doi:10.1016/j.nano.2017.12.006
   PubMed Web of Science ®Google Scholar
• Brambilla D, Le Droumaguet B, Nicolas J, et al. Nanotechnologies for Alzheimer’s disease: diagnosis, therapy, and safety issues. Nanomed Nanotechnol Biol Med. 2011;7(5):521–540. doi:10.1016/j.nano.2011.03.008
   PubMed Web of Science ®Google Scholar
• Bozdağ Pehlivan S. Nanotechnology-based drug delivery systems for targeting, imaging and diagnosis of neurodegenerative diseases. Pharm Res. 2013;30(10):2499–2511. doi:10.1007/s11095-013-1156-7
   PubMed Web of Science ®Google Scholar
• Krol S, Macrez R, Docagne F, et al. Therapeutic benefits from nanoparticles: the potential significance of nanoscience in diseases with compromise to the blood brain barrier. Chem Rev. 2013;113(3):1877–1903. doi:10.1021/cr200472g
   PubMed Web of Science ®Google Scholar
• Kaur J, Gulati M, Kapoor B, et al. Advances in designing of polymeric micelles for biomedical application in brain related diseases. Chem Biol Interact. 2022;361:109960. doi:10.1016/j.cbi.2022.109960
   PubMed Web of Science ®Google Scholar
• Aguzzi A, Lakkaraju AKK, Frontzek K. Toward therapy of human prion diseases. Annu Rev Pharmacol Toxicol. 2018;58(1):331–351. doi:10.1146/annurev-pharmtox-010617-052745
   PubMedGoogle Scholar
• Santos A, Veiga F, Figueiras A. Dendrimers as pharmaceutical excipients: synthesis, properties, toxicity and biomedical applications. Materials. 2020;13(1):65. doi:10.3390/ma13010065
   Web of Science ®Google Scholar
• Lee CC, MacKay JA, Fréchet JMJ, Szoka FC. Designing dendrimers for biological applications. Nat Biotechnol. 2005;23(12):1517–1526. doi:10.1038/nbt1171
   PubMed Web of Science ®Google Scholar
• Zhu W, Castro NJ, Shen YL, Zhang LG. Chapter 16 - Nanotechnology and 3D/4D Bioprinting for Neural Tissue Regeneration. In: Zhang LG, Fisher JP, Leong KW, editors. 3D Bioprinting and Nanotechnology in Tissue Engineering and Regenerative Medicine. 2nd ed. Academic Press; 2022:427–458. doi:10.1016/B978-0-12-824552-1.00005-0
   Google Scholar
• Lu Y, Rivera-Rodriguez A, Tay ZW, et al. Combining magnetic particle imaging and magnetic fluid hyperthermia for localized and image-guided treatment. Int j Hyperthermia. 2020;37(3):141–154. doi:10.1080/02656736.2020.1853252
   PubMed Web of Science ®Google Scholar
• Zhou H, Fan Z, Li PY, et al. Dense and dynamic polyethylene glycol shells cloak nanoparticles from uptake by liver endothelial cells for long blood circulation. ACS Nano. 2018;12(10):10130–10141. doi:10.1021/acsnano.8b04947
   PubMed Web of Science ®Google Scholar
• Rashwan AK, Karim N, Xu Y, et al. An updated and comprehensive review on the potential health effects of curcumin-encapsulated micro/nanoparticles. Crit Rev Food Sci Nutr. 2022;1(1):1–21. doi:10.1080/10408398.2022.2070906
   Google Scholar
• Souri M, Soltani M, Moradi Kashkooli F, Kiani shahvandi M. Engineered strategies to enhance tumor penetration of drug-loaded nanoparticles. J Control Release. 2022;341:227–246. doi:10.1016/j.jconrel.2021.11.024
   PubMed Web of Science ®Google Scholar
• Peng L, Liang Y, Zhong X, et al. Aptamer-conjugated gold nanoparticles targeting epidermal growth factor receptor variant III for the treatment of glioblastoma. Int J Nanomed. 2020;15:1363–1372. doi:10.2147/IJN.S238206
   PubMed Web of Science ®Google Scholar
• Salameh JW, Zhou L, Ward SM, Santa Chalarca CF, Emrick T, Figueiredo ML. Polymer-mediated gene therapy: recent advances and merging of delivery techniques. WIREs Nanomed Nanobiotechnol. 2020;12(2):e1598. doi:10.1002/wnan.1598
   Google Scholar
• Yi C, Yang Y, Liu B, He J, Nie Z. Polymer-guided assembly of inorganic nanoparticles. Chem Soc Rev. 2020;49(2):465–508. doi:10.1039/C9CS00725C
   PubMed Web of Science ®Google Scholar
• Karuppusamy C, Palanivel V. Role of nanoparticles in drug delivery system: a comprehensive review. Int J Med. 2017;9:318–325.
   Google Scholar
• Adepu S, Ramakrishna S. Controlled drug delivery systems: current status and future directions. Molecules. 2021;26(19):5905. doi:10.3390/molecules26195905
   PubMed Web of Science ®Google Scholar
• Tang F, Li L, Chen D. Mesoporous silica nanoparticles: synthesis, biocompatibility and drug delivery. Adv Mater. 2012;24(12):1504–1534. doi:10.1002/adma.201104763
   PubMed Web of Science ®Google Scholar
• Yin Q, Shen J, Zhang Z, Yu H, Li Y. Reversal of multidrug resistance by stimuli-responsive drug delivery systems for therapy of tumor. Adv. Drug Delivery Rev. 2013;65(13):1699–1715. doi:10.1016/j.addr.2013.04.011
   PubMed Web of Science ®Google Scholar
• Nguyen CV, Ye Q, Meyyappan M. Carbon nanotube tips for scanning probe microscopy: fabrication and high aspect ratio nanometrology. Meas Sci Technol. 2005;16(11):2138. doi:10.1088/0957-0233/16/11/003
   Web of Science ®Google Scholar
• Klumpp C, Kostarelos K, Prato M, Bianco A. Functionalized carbon nanotubes as emerging nanovectors for the delivery of therapeutics. Biochimica et Biophysica Acta. 2006;1758(3):404–412. doi:10.1016/j.bbamem.2005.10.008
   PubMed Web of Science ®Google Scholar
• Ranjita Misra SSP, Sanjeeb K. Nanoparticles: a Boon to Drug Delivery, Therapeutics, Diagnostics and Imaging. In: Nanomedicine in Cancer. Jenny Stanford Publishing; 2017.
   Google Scholar
• Soni S, Ruhela RK, Medhi B. Nanomedicine in Central Nervous System (CNS) disorders: a present and future prospective. Adv Pharm Bull. 2016;6(3):319–335. doi:10.15171/apb.2016.044
   PubMedGoogle Scholar
• Gaur M, Misra C, Yadav AB, et al. Biomedical applications of carbon nanomaterials: fullerenes, quantum dots, nanotubes, nanofibers, and graphene. Materials. 2021;14(20):5978. doi:10.3390/ma14205978
   PubMed Web of Science ®Google Scholar
• Gao G, Ahn M, Cho WW, Kim BS, Cho DW. 3D printing of pharmaceutical application: drug screening and drug delivery. Pharmaceutics. 2021;13(9):1373. doi:10.3390/pharmaceutics13091373
   PubMed Web of Science ®Google Scholar
• Janzen D, Bakirci E, Wieland A, Martin C, Dalton PD, Villmann C. Cortical neurons form a functional neuronal network in a 3D printed reinforced matrix. Adv. Healthcare Mater. 2020;9(9):1901630. doi:10.1002/adhm.201901630
   Web of Science ®Google Scholar
• Ye W, Li H, Yu K, et al. 3D printing of gelatin methacrylate-based nerve guidance conduits with multiple channels. Mater Des. 2020;192:108757. doi:10.1016/j.matdes.2020.108757
   Web of Science ®Google Scholar
• Saylam E, Akkaya Y, Ilhan E, et al. Levodopa-Loaded 3D-printed poly (lactic) acid/chitosan neural tissue scaffold as a promising drug delivery system for the treatment of parkinson’s disease. Appl Sci. 2021;11(22):10727. doi:10.3390/app112210727
   Google Scholar
• Perkušić M, Nižić Nodilo L, Ugrina I, et al. Chitosan-based thermogelling system for nose-to-brain donepezil delivery: optimising formulation properties and nasal deposition profile. Pharmaceutics. 2023;15(6):1660. doi:10.3390/pharmaceutics15061660
   PubMed Web of Science ®Google Scholar
• Fujimaki H, Uchida K, Inoue G, et al. Oriented collagen tubes combined with basic fibroblast growth factor promote peripheral nerve regeneration in a 15 mm sciatic nerve defect rat model. J Biomed Mater Res A. 2017;105(1):8–14. doi:10.1002/jbm.a.35866
   PubMed Web of Science ®Google Scholar
• Wu Z, Li Q, Xie S, Shan X, Cai Z. In vitro and in vivo biocompatibility evaluation of a 3D bioprinted gelatin-sodium alginate/rat Schwann-cell scaffold. Mater Sci Eng C Mater Biol Appl. 2020;109:110530. doi:10.1016/j.msec.2019.110530
   PubMed Web of Science ®Google Scholar
• Gu Q, Tomaskovic-Crook E, Lozano R, et al. Functional 3D neural mini-tissues from printed gel-based bioink and human neural stem cells. Adv Healthc Mater. 2016;5(12):1429–1438. doi:10.1002/adhm.201600095
   PubMed Web of Science ®Google Scholar
• Gander C, Shi K, Nokhodchi A, Lam M. A review of the Benefits 3D printing brings to patients with neurological diseases. Pharmaceutics. 2023;15(3):892. doi:10.3390/pharmaceutics15030892
   PubMed Web of Science ®Google Scholar
• Thomas M, Willerth SM. 3-D bioprinting of neural tissue for applications in cell therapy and drug screening. Front Bioeng Biotechnol. 2017;5:69. doi:10.3389/fbioe.2017.00069
   PubMed Web of Science ®Google Scholar
• Amiri E, Sanjarnia P, Sadri B, Jafarkhani S, Khakbiz M. Recent advances and future directions of 3D to 6D printing in brain cancer treatment and neural tissue engineering. Biomedical Materials. 2023;18. doi:10.1088/1748-605X/ace9a4
   Web of Science ®Google Scholar
• Kristiawan RB, Imaduddin F, Ariawan D, Arifin Z. A review on the fused deposition modeling (FDM) 3D printing: filament processing, materials, and printing parameters. Open Eng. 2021;11(1):639–649. doi:10.1515/eng-2021-0063
   Web of Science ®Google Scholar
• Zhu S, Zhang T, Zheng L, et al. Combination strategies to maximize the benefits of cancer immunotherapy. J Hematol Oncol. 2021;14(1):156. doi:10.1186/s13045-021-01164-5
   PubMed Web of Science ®Google Scholar
• Rana I, Oh J, Baig J, Moon JH, Son S, Nam J. Nanocarriers for cancer nano-immunotherapy. Drug Deliv Transl Res. 2023;13(7):1936–1954. doi:10.1007/s13346-022-01241-3
   PubMed Web of Science ®Google Scholar
• Bulcha JT, Wang Y, Ma H, Tai PWL, Gao G. Viral vector platforms within the gene therapy landscape. Sig Transduct Target Ther. 2021;6(1):1–24. doi:10.1038/s41392-021-00487-6
   PubMed Web of Science ®Google Scholar
• Smith MW, Gumbleton M. Endocytosis at the blood–brain barrier: from basic understanding to drug delivery strategies. J Drug Targeting. 2006;14(4):191–214. doi:10.1080/10611860600650086
   PubMed Web of Science ®Google Scholar
• Chang EL, Ting CY, Hsu PH, et al. Angiogenesis-targeting microbubbles combined with ultrasound-mediated gene therapy in brain tumors. J Control Release. 2017;255:164–175. doi:10.1016/j.jconrel.2017.04.010
   PubMed Web of Science ®Google Scholar
• IAW H, Lam PYP, Hui KM. Identification and characterization of novel human glioma-specific peptides to potentiate tumor-specific gene delivery. Human Gene Therapy. 2004;15(8):719–732. doi:10.1089/1043034041648372
   PubMed Web of Science ®Google Scholar
• Yahya EB, Alqadhi AM. Recent trends in cancer therapy: a review on the current state of gene delivery. Life Sci. 2021;269:119087. doi:10.1016/j.lfs.2021.119087
   PubMed Web of Science ®Google Scholar
• Unnisa A, Greig NH, Kamal MA. Nanotechnology-based gene therapy as a credible tool in the treatment of Alzheimer’s disease. Neural Regen Res. 2023;18(10):2127–2133. doi:10.4103/1673-5374.369096
   PubMed Web of Science ®Google Scholar
• Yu C, Li L, Hu P, et al. Recent advances in stimulus-responsive nanocarriers for gene therapy. Adv Sci. 2021;8(14):2100540. doi:10.1002/advs.202100540
   Web of Science ®Google Scholar
• Sandoz D, Boisvieux-Ulrich E, Laugier C, Brard E. Interactions of estradiol benzoate and progesterone on the development of the oviduct in quail. II. (Coturnix coturnix japonica). Ultrastructural studies of two types of responses obtained by varying doses of estradiol benzoate injected. Gen Comp Endocrinol. 1975;26(4):451–467. doi:10.1016/0016-6480(75)90168-9
   PubMed Web of Science ®Google Scholar
• Sudhakar V, Richardson RM. Gene therapy for neurodegenerative diseases. Neurotherapeutics. 2019;16(1):166–175. doi:10.1007/s13311-018-00694-0
   PubMed Web of Science ®Google Scholar
• Berndt P, Winkler L, Cording J, et al. Tight junction proteins at the blood-brain barrier: far more than claudin-5. Cell Mol Life Sci. 2019;76(10):1987–2002. doi:10.1007/s00018-019-03030-7
   PubMed Web of Science ®Google Scholar
• Negro S, Boeva L, Slowing K, Fernandez-Carballido A, Garcia-García L, Barcia E. Efficacy of ropinirole-loaded PLGA microspheres for the reversion of rotenone- induced parkinsonism. Curr Pharm Des. 2017;23(23):3423–3431. doi:10.2174/1381612822666160928145346
   PubMed Web of Science ®Google Scholar
• National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333(24):1581–1588. doi:10.1056/NEJM199512143332401
   PubMed Web of Science ®Google Scholar
• Celentano W, Pizzocri M, Moncalvo F, et al. Functional Poly(ε-caprolactone)/Poly(ethylene glycol) copolymers with complex topologies for doxorubicin delivery to a proteinase-rich tumor environment. ACS Appl Polym Mater. 2022;4(11):8043–8056. doi:10.1021/acsapm.2c00897
   Google Scholar
• Han L, Jiang C. Evolution of blood–brain barrier in brain diseases and related systemic nanoscale brain-targeting drug delivery strategies. Acta Pharmaceutica Sinica B. 2021;11(8):2306–2325. doi:10.1016/j.apsb.2020.11.023
   PubMed Web of Science ®Google Scholar
• Zuardi AW, Crippa JS, Hallak JEC, Moreira FA, Guimarães FS. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz J Med Biol Res. 2006;39:421–429. doi:10.1590/S0100-879X2006000400001
   PubMed Web of Science ®Google Scholar
• Kondiah PPD, Choonara YE, Kondiah PJ, et al. 17 - Nanocomposites for therapeutic application in multiple sclerosis. In: Inamuddin AAM, Mohammad A, editors. Applications of Nanocomposite Materials in Drug Delivery. Woodhead Publishing Series in Biomaterials. Woodhead Publishing; 2018:391–408. doi:10.1016/B978-0-12-813741-3.00017-0
   Google Scholar
• Singh N, Miner A, Hennis L, Mittal S. Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review. Cancer Drug Resist. 2021;4(1):17–43. doi:10.20517/cdr.2020.79
   PubMedGoogle Scholar
• Teleanu RI, Preda MD, Niculescu AG, et al. Current strategies to enhance delivery of drugs across the blood-brain barrier. Pharmaceutics. 2022;14(5):987. doi:10.3390/pharmaceutics14050987
   PubMed Web of Science ®Google Scholar
• Barbara R, Belletti D, Pederzoli F, et al. Novel Curcumin loaded nanoparticles engineered for blood-brain barrier crossing and able to disrupt abeta aggregates. Int J Pharm. 2017;526(1–2):413–424. doi:10.1016/j.ijpharm.2017.05.015
   PubMed Web of Science ®Google Scholar
• Englert C, Trützschler AK, Raasch M, et al. Crossing the blood-brain barrier: glutathione-conjugated poly(ethylene imine) for gene delivery. J Control Release. 2016;241:1–14. doi:10.1016/j.jconrel.2016.08.039
   PubMed Web of Science ®Google Scholar
• Gao S, Tian H, Xing Z, et al. A non-viral suicide gene delivery system traversing the blood brain barrier for non-invasive glioma targeting treatment. J Control Release. 2016;243:357–369. doi:10.1016/j.jconrel.2016.10.027
   PubMed Web of Science ®Google Scholar
• O Q, M Y, Z W, T J, C Z, Z Q. New advances in brain-targeting nano-drug delivery systems for Alzheimer’s disease. J Drug Targeting. 2022;30(1). doi:10.1080/1061186X.2021.1927055
   Web of Science ®Google Scholar
• Rassu G, Soddu E, Posadino AM, et al. Nose-to-brain delivery of BACE1 siRNA loaded in solid lipid nanoparticles for Alzheimer’s therapy. Colloids Surf B Biointerfaces. 2017;152:296–301. doi:10.1016/j.colsurfb.2017.01.031
   PubMed Web of Science ®Google Scholar
• Ng EP, Mintova S. Nanoporous materials with enhanced hydrophilicity and high water sorption capacity. Microporous Mesoporous Mater. 2008;114(1):1–26. doi:10.1016/j.micromeso.2007.12.022
   Web of Science ®Google Scholar
• Niu S, Zhang LK, Zhang L, et al. Inhibition by multifunctional magnetic nanoparticles loaded with Alpha-Synuclein RNAi Plasmid in a parkinson’s disease model. Theranostics. 2017;7(2):344–356. doi:10.7150/thno.16562
   PubMed Web of Science ®Google Scholar
• Pan X, Veroniaina H, Su N, et al. Applications and developments of gene therapy drug delivery systems for genetic diseases. Asian J Pharm Sci. 2021;16(6):687–703. doi:10.1016/j.ajps.2021.05.003
   PubMed Web of Science ®Google Scholar
• Ishizu N, Yui D, Hebisawa A, et al. Impaired striatal dopamine release in homozygous Vps35 D620N knock-in mice. Hum Mol Genet. 2016;25(20):4507–4517. doi:10.1093/hmg/ddw279
   PubMed Web of Science ®Google Scholar
• Han L, Cai Q, Tian D, et al. Targeted drug delivery to ischemic stroke via chlorotoxin-anchored, lexiscan-loaded nanoparticles. Nanomedicine. 2016;12(7):1833–1842. doi:10.1016/j.nano.2016.03.005
   PubMed Web of Science ®Google Scholar
• He C, Hu Y, Yin L, Tang C, Yin C. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials. 2010;31(13):3657–3666. doi:10.1016/j.biomaterials.2010.01.065
   PubMed Web of Science ®Google Scholar
• Sun T, Zhang YS, Pang B, Hyun DC, Yang M, Xia Y. Engineered nanoparticles for drug delivery in cancer therapy. Angew Chem Int Ed. 2014;53(46):12320–12364. doi:10.1002/anie.201403036
   PubMed Web of Science ®Google Scholar
• Xie J, Shen Z, Anraku Y, Kataoka K, Chen X. Nanomaterial-based blood-brain-barrier (BBB) crossing strategies. Biomaterials. 2019;224:119491. doi:10.1016/j.biomaterials.2019.119491
   PubMed Web of Science ®Google Scholar
• Bhaskar S, Tian F, Stoeger T, et al. Multifunctional Nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: perspectives on tracking and neuroimaging. Particle Fibre Toxicol. 2010;7(1):3. doi:10.1186/1743-8977-7-3
   PubMedGoogle Scholar
• Pardeshi CV, Belgamwar VS. Direct nose to brain drug delivery via integrated nerve pathways bypassing the blood–brain barrier: an excellent platform for brain targeting. Expert Opin Drug Delivery. 2013;10(7):957–972. doi:10.1517/17425247.2013.790887
   PubMed Web of Science ®Google Scholar
• Graff CL, Pollack GM. Nasal drug administration: potential for targeted central nervous system delivery. J Pharmaceut Sci. 2005;94(6):1187–1195. doi:10.1002/jps.20318
   PubMed Web of Science ®Google Scholar
• Zhang X. Clinical Applications of Tumor-targeted Systems. In: Huang R, Wang Y editors. New Nanomaterials and Techniques for Tumor-Targeted Systems. Springer; 2020:437–456. doi:10.1007/978-981-15-5159-8_13.
   Google Scholar
• Correia AC, Monteiro AR, Silva R, Moreira JN, Sousa Lobo JM, Silva AC. Lipid nanoparticles strategies to modify pharmacokinetics of central nervous system targeting drugs: crossing or circumventing the blood–brain barrier (BBB) to manage neurological disorders. Adv. Drug Delivery Rev. 2022;189:114485. doi:10.1016/j.addr.2022.114485
   PubMed Web of Science ®Google Scholar
• De Martini LB, Sulmona C, Brambilla L, Rossi D. Cell-penetrating peptides as valuable tools for nose-to-brain delivery of biological drugs. Cells. 2023;12(12):1643. doi:10.3390/cells12121643
   PubMed Web of Science ®Google Scholar
• Bhatia S. Nanoparticles Types, Classification, Characterization, Fabrication Methods and Drug Delivery Applications. In: Bhatia S editor. Natural Polymer Drug Delivery Systems: Nanoparticles, Plants, and Algae. Springer International Publishing; 2016:33–93. doi:10.1007/978-3-319-41129-3_2.
   Google Scholar
• Tan Q, Zhao S, Xu T, et al. Getting drugs to the brain: advances and prospects of organic nanoparticle delivery systems for assisting drugs to cross the blood–brain barrier. J Mat Chem B. 2022;10(45):9314–9333. doi:10.1039/D2TB01440H
   PubMed Web of Science ®Google Scholar
• Kaur N, Kumar V, Mahender T, et al. Chapter 5 - Nanomedical drug delivery for neurodegenerative disease. In: Yadav AK, Shukla R, Flora SJS, editors. Nanomedical Drug Delivery for Neurodegenerative Diseases. Academic Press; 2022:67–79. doi:10.1016/B978-0-323-85544-0.00016-2
   Google Scholar
• Bolhassani A. Potential efficacy of cell-penetrating peptides for nucleic acid and drug delivery in cancer. Biochimica et Biophysica Acta. 2011;1816(2):232–246. doi:10.1016/j.bbcan.2011.07.006
   PubMed Web of Science ®Google Scholar
• Fonseca SB, Pereira MP, Kelley SO. Recent advances in the use of cell-penetrating peptides for medical and biological applications. Adv. Drug Delivery Rev. 2009;61(11):953–964. doi:10.1016/j.addr.2009.06.001
   PubMed Web of Science ®Google Scholar
• Chugh A, Eudes F, Shim YS. Cell-penetrating peptides: nanocarrier for macromolecule delivery in living cells. IUBMB Life. 2010;62(3):183–193. doi:10.1002/iub.297
   PubMed Web of Science ®Google Scholar
• Hervé F, Ghinea N, Scherrmann JM. CNS delivery via adsorptive transcytosis. AAPS J. 2008;10(3):455–472. doi:10.1208/s12248-008-9055-2
   PubMed Web of Science ®Google Scholar
• Tashima T. Smart strategies for therapeutic agent delivery into brain across the blood–brain barrier using receptor-mediated transcytosis. Chem Pharm Bull. 2020;68(4):316–325. doi:10.1248/cpb.c19-00854
   PubMed Web of Science ®Google Scholar
• Toth AE, Holst MR, Nielsen MS. Vesicular transport machinery in brain endothelial cells: what we know and what we do not. Curr Pharm Des. 2020;26(13):1405–1416. doi:10.2174/1381612826666200212113421
   PubMed Web of Science ®Google Scholar
• Trompetero A, Gordillo A, Del Pilar MC, Cristina V, Bustos Cruz RH. Alzheimer’s disease and parkinson’s disease: a review of current treatment adopting a nanotechnology approach. Curr Pharm Des. 2018;24(1):22–45. doi:10.2174/1381612823666170828133059
   PubMed Web of Science ®Google Scholar
• Kadry H, Noorani B, Cucullo L. A blood-brain barrier overview on structure, function, impairment, and biomarkers of integrity. Fluids Barriers CNS. 2020;17(1):69. doi:10.1186/s12987-020-00230-3
   PubMed Web of Science ®Google Scholar
• Nguyen TT, Nguyen TTD, Tran NMA, Van Vo G. Lipid-based nanocarriers via nose-to-brain pathway for central nervous system disorders. Neurochem Res. 2022;47(3):552–573. doi:10.1007/s11064-021-03488-7
   PubMed Web of Science ®Google Scholar
• Pandit R, Chen L, Götz J. The blood-brain barrier: physiology and strategies for drug delivery. Adv. Drug Delivery Rev. 2020;165–166:1–14. doi:10.1016/j.addr.2019.11.009
   PubMed Web of Science ®Google Scholar
• Montegiove N, Calzoni E, Emiliani C, Cesaretti A. Biopolymer nanoparticles for nose-to-brain drug delivery: a new promising approach for the treatment of neurological diseases. J Functional Biomaterials. 2022;13(3):125. doi:10.3390/jfb13030125
   PubMed Web of Science ®Google Scholar
• Zha S, Wong KL, All AH. Intranasal delivery of functionalized polymeric nanomaterials to the brain. Adv Healthcare Mater. 2022;11(11):2102610. doi:10.1002/adhm.202102610
   Web of Science ®Google Scholar
• Xie A, Hanif S, Ouyang J, et al. Stimuli-responsive prodrug-based cancer nanomedicine. eBioMedicine. 2020:56. doi:10.1016/j.ebiom.2020.102821
   Web of Science ®Google Scholar
• Teleanu DM, Chircov C, Grumezescu AM, Teleanu RI. Neuronanomedicine: an up-to-date overview. Pharmaceutics. 2019;11(3):101. doi:10.3390/pharmaceutics11030101
   PubMed Web of Science ®Google Scholar
• Aryal M, Arvanitis CD, Alexander PM, McDannold N. Ultrasound-mediated blood–brain barrier disruption for targeted drug delivery in the central nervous system. Adv. Drug Delivery Rev. 2014;72:94–109. doi:10.1016/j.addr.2014.01.008
   PubMed Web of Science ®Google Scholar
• D’Agata F, Ruffinatti FA, Boschi S, et al. Magnetic nanoparticles in the central nervous system: targeting principles, applications and safety issues. Molecules. 2017;23(1):9. doi:10.3390/molecules23010009
   PubMed Web of Science ®Google Scholar
• Chatterjee DK, Fong LS, Zhang Y. Nanoparticles in photodynamic therapy: an emerging paradigm. Adv. Drug Delivery Rev. 2008;60(15):1627–1637. doi:10.1016/j.addr.2008.08.003
   PubMed Web of Science ®Google Scholar
• Rondon A, Mahri S, Morales-Yanez F, Dumoulin M, Vanbever R. Protein engineering strategies for improved pharmacokinetics. Adv Funct Mater. 2021;31(44):2101633. doi:10.1002/adfm.202101633
   Web of Science ®Google Scholar
• Arvizo RR, Bhattacharyya S, Kudgus RA, Giri K, Bhattacharya R, Mukherjee P. Intrinsic therapeutic applications of noble metal nanoparticles: past, present and future. Chem Soc Rev. 2012;41(7):2943–2970. doi:10.1039/C2CS15355F
   PubMed Web of Science ®Google Scholar
• Kim SS, Noh YH, Yoon OJ, Yoo SH. Carbon nanotubes serving as stem cell scaffold. Available from: https://patents.google.com/patent/US20090148417A1/en. Accessed September 14, 2023.
   Google Scholar
• Chountoulesi M, Demetzos C. Promising nanotechnology approaches in treatment of autoimmune diseases of central nervous system. Brain Sci. 2020;10(6):338. doi:10.3390/brainsci10060338
   PubMed Web of Science ®Google Scholar
• Reddy JR. Preventive and therapeutic vaccine for Alzheimer’s disease. Available from: https://patents.google.com/patent/US20100173004A1/en. Accessed September 14, 2023.
   Google Scholar
• Barenholz Y, Ovadia H, Kizelsztein P. Liposomal formulations comprising an amphipathic weak base like tempamine for treatment of neurodegenerative conditions. 2011. Available from: https://patents.google.com/patent/US20110027351A1/en. Accessed September 14, 2023.
   Google Scholar
• Schwarz J, Weisspapir M. Colloidal solid lipid vehicle for pharmaceutical use. Available from: https://patents.google.com/patent/US20060222716A1/en. Accessed September 14, 2023.
   Google Scholar
• Sung HW, Lin YH, Chen MC, Tu H. Nanoparticles for drug delivery. Available from: https://patents.google.com/patent/US20070237827A1/en. Accessed September 14, 2023.
   Google Scholar
• Nelson T, Quattrone A, Alkon D. Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier. Available from: https://patents.google.com/patent/US7682627B2/en. Accessed September 14, 2023.
   Google Scholar
• Duskey JT, Belletti D, Pederzoli F, et al. Chapter One - Current Strategies for the Delivery of Therapeutic Proteins and Enzymes to Treat Brain Disorders. In: Sharma HS, Sharma A, editors. International Review of Neurobiology. Vol 137. Nanomedicine in Central Nervous System Injury and Repair. Academic Press; 2017:1–28. doi:10.1016/bs.irn.2017.08.006
   Google Scholar
• Khafagy ES, Morishita M, Onuki Y, Takayama K. Current challenges in non-invasive insulin delivery systems: a comparative review. Adv Drug Delivery Rev. 2007;59(15):1521–1546. doi:10.1016/j.addr.2007.08.019
   PubMed Web of Science ®Google Scholar
• Gänger S, Schindowski K. Tailoring formulations for intranasal nose-to-brain delivery: a review on architecture, physico-chemical characteristics and mucociliary clearance of the nasal olfactory mucosa. Pharmaceutics. 2018;10(3):116. doi:10.3390/pharmaceutics10030116
   PubMed Web of Science ®Google Scholar
• Salunkhe S, Basak M, Chitkara D, Mittal A. Surface functionalization of exosomes for target-specific delivery and in vivo imaging & tracking: strategies and significance. J Control Release. 2020;326:599–614. doi:10.1016/j.jconrel.2020.07.042
   PubMed Web of Science ®Google Scholar
• Hinge NS, Kathuria H, Pandey MM. Engineering of structural and functional properties of nanotherapeutics and nanodiagnostics for intranasal brain targeting in Alzheimer’s. Appl Mater Today. 2022;26:101303. doi:10.1016/j.apmt.2021.101303
   Web of Science ®Google Scholar
• Weber WA, Czernin J, Anderson CJ, et al. The future of nuclear medicine, molecular imaging, and theranostics. J Nucl Med. 2020;61(Supplement 2):263S–272S. doi:10.2967/jnumed.120.254532
   PubMedGoogle Scholar
• Chorny M, Hood E, Levy RJ, Muzykantov VR. Endothelial delivery of antioxidant enzymes loaded into non-polymeric magnetic nanoparticles. J Control Release. 2010;146(1):144–151. doi:10.1016/j.jconrel.2010.05.003
   PubMed Web of Science ®Google Scholar
• Galliani M, Santi M, Del Grosso A, et al. Cross-linked enzyme aggregates as versatile tool for enzyme delivery: application to polymeric nanoparticles. Bioconjugate Chem. 2018;29(7):2225–2231. doi:10.1021/acs.bioconjchem.8b00206
   PubMed Web of Science ®Google Scholar
• Hamill K. Delivery of an active lysosomal enzyme using GNeosomes. J Mat Chem B. 2016;4(35):5794–5797. doi:10.1039/C6TB01387B
   PubMed Web of Science ®Google Scholar
• Mukherjee S, Madamsetty VS, Bhattacharya D, Roy Chowdhury S, Paul MK, Mukherjee A. Recent advancements of nanomedicine in neurodegenerative disorders theranostics. Adv Funct Mater. 2020;30(35):2003054. doi:10.1002/adfm.202003054
   Web of Science ®Google Scholar
• Veiga N, Diesendruck Y, Peer D. Targeted nanomedicine: lessons learned and future directions. J Control Release. 2023;355:446–457. doi:10.1016/j.jconrel.2023.02.010
   PubMed Web of Science ®Google Scholar
• Lembo D, Donalisio M, Civra A, Argenziano M, Cavalli R. Nanomedicine formulations for the delivery of antiviral drugs: a promising solution for the treatment of viral infections. Expert Opin Drug Delivery. 2018;15(1):93–114. doi:10.1080/17425247.2017.1360863
   PubMed Web of Science ®Google Scholar
• Blau R, Krivitsky A, Epshtein Y, Satchi-Fainaro R. Are nanotheranostics and nanodiagnostics-guided drug delivery stepping stones towards precision medicine? Drug Resist Updates. 2016;27:39–58. doi:10.1016/j.drup.2016.06.003
   PubMed Web of Science ®Google Scholar
• Swift B, Jain L, White C, et al. Innovation at the intersection of clinical trials and real-world data science to advance patient care. Clin Transl Sci. 2018;11(5):450–460. doi:10.1111/cts.12559
   PubMed Web of Science ®Google Scholar
• Mura S, Couvreur P. Nanotheranostics for personalized medicine. Adv Drug Delivery Rev. 2012;64(13):1394–1416. doi:10.1016/j.addr.2012.06.006
   PubMed Web of Science ®Google Scholar
• Bhaladhare S, Bhattacharjee S. Chemical, physical, and biological stimuli-responsive nanogels for biomedical applications (mechanisms, concepts, and advancements): a review. Int J Biol Macromol. 2023;226:535–553. doi:10.1016/j.ijbiomac.2022.12.076
   PubMed Web of Science ®Google Scholar
• Kaushik A, Jayant RD, Bhardwaj V, Nair M. Personalized nanomedicine for CNS diseases. Drug Discovery Today. 2018;23(5):1007–1015. doi:10.1016/j.drudis.2017.11.010
   PubMed Web of Science ®Google Scholar
• Mishra AK, Das R, Sahoo S, Biswal B. Chapter Ten - Global regulations and legislations on nanoparticles usage and application in diverse horizons. In: Turan NB, Engin GO, Bilgili MS editors. Comprehensive Analytical Chemistry. Vol 99. Environmental Nanotechnology: Implications and Applications. Elsevier; 2022:261–290. doi:10.1016/bs.coac.2021.12.004.
   Google Scholar
• Sztandera K, Gorzkiewicz M, Klajnert-Maculewicz B. Gold nanoparticles in cancer treatment. Mol Pharm. 2019;16(1):1–23. doi:10.1021/acs.molpharmaceut.8b00810
   PubMed Web of Science ®Google Scholar
• Bobo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR. Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date. Pharm Res. 2016;33(10):2373–2387. doi:10.1007/s11095-016-1958-5
   PubMed Web of Science ®Google Scholar
• Foulkes R, Man E, Thind J, Yeung S, Joy A, Hoskins C. The regulation of nanomaterials and nanomedicines for clinical application: current and future perspectives. Biomater Sci. 2020;8(17):4653–4664. doi:10.1039/D0BM00558D
   PubMed Web of Science ®Google Scholar
• Alphandéry E, Grand-Dewyse P, Lefèvre R, Mandawala C, Durand-Dubief M. Cancer therapy using nanoformulated substances: scientific, regulatory and financial aspects. Expert Rev Anticancer Ther. 2015;15(10):1233–1255. doi:10.1586/14737140.2015.1086647
   PubMed Web of Science ®Google Scholar
• Bregoli L, Movia D, Gavigan-Imedio JD, Lysaght J, Reynolds J, Prina-Mello A. Nanomedicine applied to translational oncology: a future perspective on cancer treatment. Nanomed Nanotechnol Biol Med. 2016;12(1):81–103. doi:10.1016/j.nano.2015.08.006
   PubMed Web of Science ®Google Scholar
• Fan AM, Alexeeff G. Nanotechnology and nanomaterials: toxicology, risk assessment, and regulations. J Nanosci Nanotech. 2010;10(12):8646–8657. doi:10.1166/jnn.2010.2493
   PubMed Web of Science ®Google Scholar
• Luijten PR, van Dongen GAMS, Moonen CT, Storm G, Crommelin DJA. Public–private partnerships in translational medicine: concepts and practical examples. J Control Release. 2012;161(2):416–421. doi:10.1016/j.jconrel.2012.03.012
   PubMed Web of Science ®Google Scholar
• Bella D, Antonietta M. Overview and update on extracellular vesicles: considerations on exosomes and their application in modern medicine. Biology. 2022;11(6):804. doi:10.3390/biology11060804
   PubMedGoogle Scholar
• R B, De JW, Re G Nanotechnology in medical applications: state-of-the-art in materials and devices. Rijksinstituut voor Volksgezondheid en Milieu RIVM; 2005. Available from: https://rivm.openrepository.com/handle/10029/7265. Accessed September 14, 2023.
   Google Scholar
• George A, Shah PA, Shrivastav PS. Natural biodegradable polymers based nano-formulations for drug delivery: a review. Int J Pharm. 2019;561:244–264. doi:10.1016/j.ijpharm.2019.03.011
   PubMed Web of Science ®Google Scholar
• Wicki A, Witzigmann D, Balasubramanian V, Huwyler J. Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications. J Control Release. 2015;200:138–157. doi:10.1016/j.jconrel.2014.12.030
   PubMed Web of Science ®Google Scholar
• Laurent S, Dutz S, Häfeli UO, Mahmoudi M. Magnetic fluid hyperthermia: focus on superparamagnetic iron oxide nanoparticles. Adv Colloid Interface Sci. 2011;166(1):8–23. doi:10.1016/j.cis.2011.04.003
   PubMed Web of Science ®Google Scholar
• Shah S, Famta P, Bagasariya D, et al. Tuning mesoporous silica nanoparticles in novel avenues of cancer therapy. Mol Pharm. 2022;19(12):4428–4452. doi:10.1021/acs.molpharmaceut.2c00374
   PubMedGoogle Scholar
• Chandrakala V, Aruna V, Angajala G. Review on metal nanoparticles as nanocarriers: current challenges and perspectives in drug delivery systems. Emergent Mater. 2022;5(6):1593–1615. doi:10.1007/s42247-021-00335-x
   PubMedGoogle Scholar
• Alshawwa SZ, Kassem AA, Farid RM, Mostafa SK, Labib GS. Nanocarrier drug delivery systems: characterization, limitations, future perspectives and implementation of artificial intelligence. Pharmaceutics. 2022;14(4):883. doi:10.3390/pharmaceutics14040883
   PubMed Web of Science ®Google Scholar
• Huynh L, Neale C, Pomès R, Allen C. Computational approaches to the rational design of nanoemulsions, polymeric micelles, and dendrimers for drug delivery. Nanomedicine. 2012;8(1):20–36. doi:10.1016/j.nano.2011.05.006
   PubMed Web of Science ®Google Scholar
• He Y, Ye Z, Liu X, et al. Can machine learning predict drug nanocrystals? J Control Release. 2020;322:274–285. doi:10.1016/j.jconrel.2020.03.043
   PubMed Web of Science ®Google Scholar
• Duarte Y, Márquez-Miranda V, Miossec MJ, González-Nilo F. Integration of target discovery, drug discovery and drug delivery: a review on computational strategies. Wiley Interdiscip Rev Nano Nanobio. 2019;11(4):e1554. doi:10.1002/wnan.1554
   PubMed Web of Science ®Google Scholar
• Gonzalez-Ibanez AM, Gonzalez-Nilo F, Cachau R. The collaboratory for structural nanobiology. Biophys J. 2009;96(3):49a. doi:10.1016/j.bpj.2008.12.151
   Google Scholar
• Ostraat ML, Mills KC, Guzan KA, Murry D. The Nanomaterial Registry: facilitating the sharing and analysis of data in the diverse nanomaterial community. Int J Nanomed. 2013;8(sup1):7–13. doi:10.2147/IJN.S40722
   PubMedGoogle Scholar